Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
Source: SeekingAlpha
2026-01-14 06:57:07 ET
More on Ipsen S.A.
- Ipsen S.A. (IPSEY) Q3 2025 Earnings Call Transcript
- Ipsen S.A. 2025 Q3 - Results - Earnings Call Presentation
- Ipsen S.A. reports Q3 results; upgrades FY outlook
- Seeking Alpha’s Quant Rating on Ipsen S.A.
- Historical earnings data for Ipsen S.A.
Read the full article on Seeking Alpha
For further details see:
Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
Ipsen
NASDAQ: IPSEF
IPSEF Trading
100.0% G/L:
$113.13 Last:
5 Volume:
$0 Open:
IPSEF Latest News
February 27, 2026 06:20:11 am
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
February 12, 2026 01:00:00 am
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
January 27, 2026 01:00:00 am
Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team
